ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said there were no undisclosed matters that would warrant an unusual movement in its stock price, according to a Hong Kong filing Friday.
Shares declined over 13% in recent afternoon trade.
The pharma company said it had taken notice of the recent unusual fluctuations in its stock price even though its operations and clinical development remained "normal."
Meanwhile, there were no material adverse changes to the company's financial position, ImmuneOnco Biopharmaceuticals said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.